Comprehensive Analysis of SLC35A2 in Pan-Cancer and Validation of Its Role in Breast Cancer

References

• Quelhas D, Correia J, Jaeken J, et al. SLC35A2-CDG: novel variant and review. Mol Genet Metab Rep. 2021;26:100717. doi:10.1016/j.ymgmr.2021.100717
   PubMed Web of Science ®Google Scholar
• Yates TM, Suri M, Desurkar A, et al. SLC35A2-related congenital disorder of glycosylation: defining the phenotype. Eur J Paediatr Neurol. 2018;22(6):1095–1102. doi:10.1016/j.ejpn.2018.08.002
   PubMed Web of Science ®Google Scholar
• Bonduelle T, Hartlieb T, Baldassari S, et al. Frequent SLC35A2 brain mosaicism in mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE). Acta Neuropathol Commun. 2021;9(1). doi:10.1186/s40478-020-01085-3
   PubMed Web of Science ®Google Scholar
• Ng BG, Sosicka P, Agadi S, et al. SLC35A2-CDG: functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported individuals. Hum Mutat. 2019;40(7):908–925. doi:10.1002/humu.23731
   PubMed Web of Science ®Google Scholar
• Cheng H, Wang S, Gao D, et al. Nucleotide sugar transporter SLC35A2 is involved in promoting hepatocellular carcinoma metastasis by regulating cellular glycosylation. Cellular Oncol. 2022;46(2):283–297.
   Web of Science ®Google Scholar
• Liu C-L, Cheng S-P, Huang W-C, et al. Aberrant expression of solute carrier family 35 member A2 correlates with tumor progression in breast cancer. In Vivo (Brooklyn). 2023;37(1):262–269. doi:10.21873/invivo.13076
   Google Scholar
• Ta HD, Minh Xuan DT, Tang W-C, et al. Novel insights into the prognosis and immunological value of the SLC35A (Solute Carrier 35A) family genes in human breast cancer. Biomedicines. 2021;9(12):1804.
   PubMed Web of Science ®Google Scholar
• Koike T, Kimura N, Miyazaki K, et al. Hypoxia induces adhesion molecules on cancer cells: a missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc Natl Acad Sci U S A. 2004;101(28):10494.
   Web of Science ®Google Scholar
• Girardi E, Cesar-Razquin A, Lindinger S, et al. A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs. Nat Chem Biol. 2020;16(4):469–+. doi:10.1038/s41589-020-0483-3
   PubMed Web of Science ®Google Scholar
• Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–W560. doi:10.1093/nar/gkz430
   PubMed Web of Science ®Google Scholar
• Lanczky A, Gyorffy B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J Med Internet Res. 2021;23(7):e27633. doi:10.2196/27633
   PubMed Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–4202. doi:10.1093/bioinformatics/btz210
   PubMed Web of Science ®Google Scholar
• Liang J-Y, Wang D-S, Lin H-C, et al. A novel ferroptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma. Int J Biol Sci. 2020;16(13):2430–2441. doi:10.7150/ijbs.45050
   PubMed Web of Science ®Google Scholar
• Darvin P, Toor SM, Nair VS, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50. doi:10.1038/s12276-018-0076-3
   PubMed Web of Science ®Google Scholar
• Danilova L, Ho WJ, Zhu Q, et al. Programmed Cell Death Ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival. Cancer Immunol Res. 2019;7(6):886–895. doi:10.1158/2326-6066.CIR-18-0822
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49(D1):D605–D612. doi:10.1093/nar/gkaa1074
   PubMed Web of Science ®Google Scholar
• Antonio MJ, Zhang C, Le A. Different tumor microenvironments lead to different metabolic phenotypes. Adv Exp Med Biol. 2021;1311:137–147.
   PubMed Web of Science ®Google Scholar
• Lu J, Liu P, Zhang R. A metabolic gene signature to predict breast cancer prognosis. Front Mol Biosci. 2022;9. doi:10.3389/fmolb.2022.900433
   Web of Science ®Google Scholar
• Swartz MA, Iida N, Roberts EW, et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res. 2012;72(10):2473–2480. doi:10.1158/0008-5472.CAN-12-0122
   PubMed Web of Science ®Google Scholar
• Yu L, Ding Y, Wan T, Deng T, Huang H, Liu J. Significance of CD47 and its association with tumor immune microenvironment heterogeneity in ovarian cancer. Front Immunol. 2021;12:768115.
   PubMed Web of Science ®Google Scholar
• Zhang S, Ma X, Zhu C, Liu L, Wang G, Yuan X. The role of myeloid-derived suppressor cells in patients with solid tumors: a meta-analysis. PLoS One. 2016;11(10):e0164514.
   PubMed Web of Science ®Google Scholar
• Condamine T, Ramachandran I, Youn J-I, Gabrilovich DI. Regulation of tumor metastasis by myeloid-derived suppressor cells. In: Caskey CT, editor. Annual Review of Medicine. Vol. 66. Annual Reviews; 2015:97–110.
   Google Scholar
• Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3–8. doi:10.1158/2326-6066.CIR-16-0297
   PubMed Web of Science ®Google Scholar
• Burke KP, Patterson DG, Liang D, Sharpe AH. Immune checkpoint receptors in autoimmunity. Curr Opin Immunol. 2023;80:102283.
   PubMed Web of Science ®Google Scholar
• Galvano A, Gristina V, Malapelle U, et al. The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. Esmo Open. 2021;6(3):100124. doi:10.1016/j.esmoop.2021.100124
   PubMed Web of Science ®Google Scholar
• van Velzen MJM, Derks S, van Grieken NCT, et al. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. Cancer Treat Rev. 2020;86. doi:10.1016/j.ctrv.2020.102024
   PubMed Web of Science ®Google Scholar
• Zhang L, Li B, Peng Y, et al. The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: a gene expression-based study. Oral Oncol. 2020;110:104943.
   PubMed Web of Science ®Google Scholar
• Cherepanova N, Shrimal S, Gilmore R. N-linked glycosylation and homeostasis of the endoplasmic reticulum. Curr Opin Cell Biol. 2016;41:57–65. doi:10.1016/j.ceb.2016.03.021
   PubMed Web of Science ®Google Scholar
• Ding J, Xu J, Deng Q, et al. Knockdown of oligosaccharyltransferase subunit ribophorin 1 induces endoplasmic-reticulum-stress-dependent cell apoptosis in breast cancer. Front Oncol. 2021;11:722624.
   PubMed Web of Science ®Google Scholar
• Cubillos-Ruiz JR, Bettigole SE, Glimcher LH. Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in cancer. Cell. 2017;168(4):692–706. doi:10.1016/j.cell.2016.12.004
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang K, Jin Y, Sheng X. Endoplasmic reticulum proteostasis control and gastric cancer. Cancer Lett. 2019;449:263–271. doi:10.1016/j.canlet.2019.01.034
   PubMed Web of Science ®Google Scholar
• Xu D, Liu Z, Liang M-X, et al. Endoplasmic reticulum stress targeted therapy for breast cancer. Cell Commun Signal. 2022;20(1). doi:10.1186/s12964-022-00964-7
   Web of Science ®Google Scholar
• Sim NS, Seo Y, Lim JS, et al. Brain somatic mutations in SLC3SA2 cause intractable epilepsy with aberrant N-glycosylation. Neurology-Genetics. 2018;4(6). doi:10.1212/NXG.0000000000000294
   PubMed Web of Science ®Google Scholar
• Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–226. doi:10.1016/j.tcb.2018.12.001
   PubMed Web of Science ®Google Scholar
• Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15(1):129.
   PubMed Web of Science ®Google Scholar
• Lu W, Kang Y. Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell. 2019;49(3):361–374. doi:10.1016/j.devcel.2019.04.010
   PubMed Web of Science ®Google Scholar